Dataset Information


Gene expression changes in 786-O cells in response to 5DC treatment.

ABSTRACT: Inactivation of the von Hippel-Lindau tumor suppressor gene, VHL, is an archetypical tumor-initiating event in clear cell renal carcinoma (ccRCC) that leads to the activation of hypoxia-inducible transcription factors (HIFs). However, VHL mutation status in ccRCC is not correlated with clinical outcome. Here we show that during ccRCC progression, cancer cells exploit diverse epigenetic alterations to empower a branch of the VHL-HIF pathway for metastasis, and the strength of this activation is associated with poor clinical outcome. By analyzing metastatic subpopulations of VHL-deficient ccRCC cells, we discovered an epigenetically altered VHL-HIF response that is specific to metastatic ccRCC. Focusing on the two most prominent pro-metastatic VHL-HIF target genes, we show that loss of polycomb repressive complex 2 (PRC2)-dependent histone H3 Lys27 trimethylation (H3K27me3) activates HIF-driven chemokine (C-X-C motif) receptor 4 (CXCR4) expression in support of chemotactic cell invasion, whereas loss of DNA methylation enables HIF-driven cytohesin 1 interacting protein (CYTIP) expression to protect cancer cells from death cytokine signals. Thus, metastasis in ccRCC is based on an epigenetically expanded output of the tumor-initiating pathway. Gene expression data from 786-O cells after 3-day treatment with 100uM 5’-aza-deoxycytidine (5DC) or vehicle (DMSO).

ORGANISM(S): Homo sapiens  

SUBMITTER: Sakari Vanharanta   Joan Massagué 

PROVIDER: E-GEOD-32298 | ArrayExpress | 2012-12-05



Similar Datasets

2012-12-05 | E-GEOD-32297 | ArrayExpress
2012-12-05 | E-GEOD-32295 | ArrayExpress
2012-12-05 | E-GEOD-32299 | ArrayExpress
2012-12-05 | E-GEOD-35417 | ArrayExpress
2009-08-27 | GSE16622 | GEO
2009-08-27 | E-GEOD-16622 | ArrayExpress
2013-05-25 | E-GEOD-47352 | ArrayExpress
| GSE102095 | GEO
2012-06-10 | GSE25540 | GEO
2020-07-02 | PXD016630 | Pride